** Gene therapy company MeiraGTx Holdings' shares MGTX.O rise 30.3% to $8.36 - highest since June 2023
** MGTX says it will collaborate with Hologen to form a joint venture called Hologen Neuro AI to develop experimental gene therapy AAV-GAD to treat Parkinson's disease
** Parkinson's disease is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues
** MGTX will receive $200 million in upfront payment for the venture and $230 million to develop the gene therapy AAV-GAD, which is currently in late-stage development
** MGTX says it will retain 30% ownership in the joint venture and will lead all clinical development and manufacturing
** Separately, MGTX posts 2024 revenue of $33.28 mln, compared to $14.02 mln a year earlier
** Up to last close, MGTX had risen 5.6% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。